Transmedos NT, UAB - financials and debts

Company age: 6 y. 5 mo.

Update

Transmedos NT - Company finances

EUR
2020
From: 2020-04-01
To: 2020-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 2,400 4,800 7,000 259,509 346,653 352,743
Profit before tax -3,356 -3,521 -1,378 -141,871 -90,633 -59,666
Net profit -3,356 -3,521 -1,378 -141,871 -90,633 -59,666
Equity 2,167,798 2,164,277 2,162,899 2,021,027 1,930,394 1,870,728
Liabilities 54,592 57,151 61,599 4,319,248 4,142,627 3,958,095
Non-current assets 2,221,154 2,221,154 2,221,154 6,211,437 5,998,482 5,785,449
Current assets 1,236 274 3,344 128,838 74,539 43,374
Total assets 2,222,390 2,221,428 2,224,498 6,340,275 6,073,021 5,828,823
Taxes paid
STI taxes - - - 39,429 71,341 72,587
Financial indicators
Revenue change y/y - +100.0% +45.8% +3607.3% +33.6% +1.8%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. -0.2% -0.2% -0.1% -2.2% -1.5% -1.0%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. -0.2% -0.2% -0.1% -7.0% -4.7% -3.2%
Profit margin Net profit margin. Shows the overall profitability of the company. -139.8% -73.4% -19.7% -54.7% -26.1% -16.9%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. -139.8% -73.4% -19.7% -54.7% -26.1% -16.9%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. 0.0 0.0 0.0 2.1 2.1 2.1
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. 1,800 2,504 7,000 259,509 346,653 352,743

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Transmedos NT - Social security debts

From To Debt, €
2026-09-05 2026-09-10 0.38
2026-08-26 2026-09-02 0.38
2026-08-23 2026-08-23 0.38
2026-07-19 2026-08-12 0.38
2026-07-16 2026-07-17 0.38
2026-06-16 2026-07-08 0.38
2026-05-17 2026-06-08 0.38
2026-03-27 2026-03-27 71.86
2026-03-17 2026-03-24 71.86
2026-03-15 2026-03-16 0.05
2026-02-18 2026-03-11 0.05
2026-01-16 2026-02-12 0.05
2025-05-16 2025-05-20 73.05
2024-01-16 2024-01-16 72.76
2023-11-22 2023-11-23 0.19
2023-11-16 2023-11-21 1.87
2023-10-25 2023-11-13 1.87
2023-10-17 2023-10-24 1.68
2023-09-18 2023-10-11 1.68
2023-08-25 2023-09-12 1.68
2023-08-17 2023-08-24 59.98
2023-07-28 2023-08-16 1.73
2023-07-26 2023-07-27 1.68
2023-07-24 2023-07-25 1.73
2023-07-18 2023-07-23 1.68
2023-05-16 2023-07-12 1.68

Transmedos NT - VMI tax arrears

The company had no tax arrears (debts) to the State Tax Inspectorate

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Transmedos NT, UAB (code 305528499) is a Private Limited Liability Company operating in rental and operating of own or leased real estate. In 2025, the company generated revenue of €352.7K, up 1.8% year on year and 35.9% over two years, showing steady top-line growth. Net profit remained negative at €59.7K, but losses narrowed from €90.6K in 2024 and €141.9K in 2023, indicating a gradual improvement in operating performance. The 2025 profit margin was -16.9%, better than -26.1% in 2024 and -54.7% in 2023. Balance sheet size decreased slightly to €5.83M, with total assets mainly concentrated in long-term assets of €5.79M. Equity stood at €1.87M and liabilities at €3.96M, giving an equity ratio of 32.1% and a debt-to-equity ratio of 2.12. Return on equity was -3.2% and return on assets -1.0%, while asset turnover remained low at 0.06x, consistent with a real estate business model. Revenue per employee was €352.7K in 2025, and profit per employee was -€59.7K.